Striking animal results, an unsolved absorption problem, and an open question about activating a receptor some cancers depend on.
Two things about SLU-PP-332 are worth establishing before anything else.
It is not a peptide. What it is: a synthetic small molecule of about 290 daltons, formula C18H14N2O2. Peptides are chains of amino acids. This shares none of that structure. It appears alongside peptides because the same vendors sell it and the same communities discuss it. A supplier describing it as a peptide is telling you something useful about their information quality.
It has never been given to a human in a clinical trial. Not once. Every efficacy finding below comes from mice. One 2025 study treated human muscle cells in a dish, which is not the same thing.
The compound activates estrogen-related receptors, or ERRs. The name misleads almost everyone who meets it.
These receptors have nothing to do with oestrogen. They do not bind it, and switching them on does not change oestrogen levels. They are called orphan receptors, because when they were found nobody knew what activated them naturally. The name comes from their shape: they look similar to oestrogen receptors. That resemblance is the whole basis of it.
The family has three members: alpha, beta and gamma. This compound switches on every one of them, which makes it a panagonist. Its strongest effect is at ERR alpha.
ERR alpha is sometimes called a master regulator of energy metabolism. It governs the genes behind building new mitochondria, burning fat for fuel, and running the electron transport chain.
It is also switched on by exercise. Endurance training raises ERR alpha activity. That is part of how muscle adapts, giving more mitochondria, better fat burning and improved endurance.
SLU-PP-332 activates the same receptor without the training. Hence "exercise in a pill."
The mechanism has been confirmed properly, which is worth noting. Researchers repeated the exercise experiment in mice lacking the ERR alpha gene, and the effects vanished entirely. That is how you demonstrate a result comes from the intended target rather than something incidental.
Exercise activates hundreds of pathways at once. AMPK, mTOR, BDNF, IGF-1, myokine release, signals to bone, effects on immune function.
This compound activates one.
It copies a fragment of a much larger system. Whatever it does, it is not a substitute for training. Expecting otherwise misreads what a single-target drug can do.
Exercise capacity (Billon and colleagues, ACS Chemical Biology, 2023). Treated mice ran 70% longer and 45% further than controls. They also had more oxidative muscle fibres and higher mitochondrial DNA content. The knockout confirmation came from this study.
Metabolic syndrome (Billon and colleagues, Journal of Pharmacology and Experimental Therapeutics, 2024). Obese mice lost roughly 12% of body weight over 28 days. Energy expenditure and fat oxidation rose, glucose tolerance improved. Food intake did not change, and neither did activity — the metabolism was simply running hotter.
Ageing kidney (Wang and colleagues, American Journal of Pathology, 2023). Eight weeks in 21-month-old mice reversed age-related protein leakage, cell loss and mitochondrial dysfunction. Human kidney tissue showed a similar age-related decline in the same pathway. The treatment itself was tested only in mice.
Heart failure (Xu and colleagues, Circulation, 2024). In pressure-overload heart failure, treatment improved ejection fraction, reduced fibrosis and increased survival. Here ERR gamma, not alpha, was the main mediator.
Human muscle cells (Bonanni and colleagues, Frontiers in Physiology, 2025). Cells from inactive elderly women showed reduced oxidative stress and improved fusion into mature fibres. Encouraging, and still cell culture.
Every one of those studies used intraperitoneal injection in a DMSO-based vehicle. No study has tested oral dosing, and the longest treatment ran eight weeks.
This is the practical heart of it, and it explains why user reports are so contradictory.
The compound is hydrophobic. It will not dissolve in water. It goes into DMSO sparingly, and into ethanol only slightly.
To be absorbed from the gut, a compound must dissolve and cross a watery layer lining the intestinal wall. A dry powder that will not dissolve in water crosses it unpredictably. How much gets through depends on bile flow, what was eaten with it, and individual gut differences.
That predicts exactly the pattern the forums show: some people report noticeable effects, many report nothing whatsoever. Those are not contradictory reports about the same exposure. They are reports about wildly different exposures.
Two consequences follow.
Published oral bioavailability figures do not exist. Any specific percentage circulating online is invented, because no study has measured it.
The developers are still injecting it. Every published study uses injection, and the researchers have written that the structure needs improving for oral delivery. If oral administration worked well, the people who made the compound would be using it.
Scale the mouse doses the standard way and the human-equivalent figure lands around 140 to 560 mg a day, depending which study you start from. That figure also assumes full absorption. Injection provides that. Swallowing does not.
Capsules on the market contain between 100 micrograms and a few milligrams.
So the amount sold is a small fraction of what produced effects in mice. That is before absorption losses are counted. Both problems point the same way.
This needs stating carefully, because the honest answer is uncertainty rather than alarm.
No study has shown that SLU-PP-332 causes cancer.
The concern is structural. ERR alpha is a receptor several cancers appear to rely on. In one type of breast cancer it matters for growth, and suppressing it roughly doubled how long tumours took to double in mouse studies. It has also been linked to cancer stem cell traits, and to VEGF, which tumours use to build a blood supply. In lung cancer cells it drove growth, migration and invasion. Across several cancer types, blocking it slows tumour growth.
So the open question is what happens when a receptor some cancers depend on is switched on continuously. Particularly in someone with undetected early disease. Particularly over years.
Nobody knows. The mouse studies ran 28 days to 8 weeks. That is far too short to spot tumour development even if it were happening. This is an unexamined risk, not a demonstrated harm, and the difference between those two matters. It is also a reason the compound warrants more caution than its mouse data alone would suggest.
HDL cholesterol fell in the metabolic syndrome study, alongside reductions in total cholesterol and triglycerides. Lower HDL is generally considered unfavourable, and it was the one clearly adverse signal in the animal work.
The compound is not approved anywhere. WADA prohibits it under S0, which covers substances with no approval for human therapeutic use. A 2026 study from the UCLA Olympic Analytical Laboratory mapped 22 metabolites specifically to support doping control. Any tested athlete should treat it as both banned and detectable.
The animal data is consistent and, in places, striking. The mechanism is properly demonstrated. The kidney and cardiac findings are interesting well beyond fat loss.
Set against that, the gaps are large. There is no human exposure data at all. The developers have not solved an oral formulation. Products contain a fraction of the studied dose. There is an unresolved question about switching on a receptor implicated in tumour growth. And no safety data runs beyond eight weeks in any species.
That is not a balanced ledger. It is a compound at an early stage of investigation being sold as though it were further along.
This article explains published research and the rules around it. It carries no dose, no protocol, and no claim that any compound treats, cures or prevents a condition in anyone. Where the evidence is thin we say so. See our editorial standards.
Research-grade material, sold for laboratory research use. We link to a single supplier rather than a list, so you know exactly where the recommendation goes. Check the certificate of analysis against what a COA can and cannot show before you buy anything.
Commercial link. Nothing on this page is a dose, a protocol, or a claim that this compound treats or prevents any condition.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
An open study found sleep normalised in six of seven patients. The controlled study by the same investigator found weak effects and said so. The difference between them is a placebo arm.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
